Vanessa Salazar

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

Harold J. Burstein, Anna Maria Storniolo, Sandra Franco et al. · Annals of Oncology · 2008 · 205 citations

Metastatic Breast Cancer, Breast Oncology, Medicine +7

Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy

Stephen Johnston, Maureen Trudeau, Bella Kaufman et al. · Journal of Clinical Oncology · 2008 · 189 citations · Full text

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

Bella Kaufman, Maureen Trudeau, Ahmad Awada et al. · The Lancet Oncology · 2009 · 118 citations · Full text

Breast Oncology, Medicine, Lapatinib Monotherapy +8

Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Lapatinib Plus Paclitaxel in Patients With Inflammatory Breast Cancer

Hamouda Boussen, Massimo Cristofanilli, Tal Zaks et al. · Journal of Clinical Oncology · 2010 · 70 citations · Full text

Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer

K. Blackwell, Harold J. Burstein, Mark D. Pegram et al. · Journal of Clinical Oncology · 2005 · 66 citations

Breast Oncology, Pathology, Phase Ii Study +19